Letter: Long-Term Safety and Effectiveness of Lebrikizumab Treatment for Moderate-to-Severe Atopic Dermatitis Stratified by Age Groups in Real-World Clinical Practice in Japan
Restricted accessLetterFirst published online 2026
Letter: Long-Term Safety and Effectiveness of Lebrikizumab Treatment for Moderate-to-Severe Atopic Dermatitis Stratified by Age Groups in Real-World Clinical Practice in Japan
SilverbergJI, Guttman-YasskyE, ThaçiD, et al.; ADvocate1 and ADvocate2 Investigators. Two phase 3 trials of Lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023; 388(12):1080–1091.
2.
BlauveltA, ThyssenJP, Guttman-YasskyEIII,et al.Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase trials. Br J Dermatol. 2023; 188(6):740–748.
3.
SimpsonEL, GooderhamM, WollenbergA, et al.; ADhere Investigators. Efficacy and safety of Lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: A randomized clinical trial (ADhere). JAMA Dermatol. 2023; 159(2):182–191.
4.
HaginoT, UchiyamaA, OndaM, et al.24-Week real-world effectiveness and safety of Lebrikizumab for atopic dermatitis in Japan: An analysis stratified by prior systemic therapy. Dermatitis. 2025.
5.
AvalloneG, BombelliA, GargiuloL, et al.Effectiveness, safety, and health-related quality of life in moderate-to-severe atopic dermatitis treated with Lebrikizumab: A 16-week nationwide retrospective cohort study. Dermatol Ther (Heidelb). 2025; 15(12):3671–3688.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
